Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis

Avki, Sırrı; Türütoğlu, Hülya; Şimşek, Atilla; Ünsal, Alaattin

doi:10.1016/j.vetimm.2003.10.003

Cited by 13 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, NDV had been found to stimulate the host immunity to produce cytokines, such as IFN- α ,IFN- β , TNF- α , and IL-1, which in turn leads to the activation of NK cells, macrophages, and sensitized T cells [19, 28, 29]. According to Fournier et al [21], paracrine stimulation of IFN responses is through either exposure of viral HN proteins or by viral RNA.…”

Section: Immunostimulatory Property Of Ndvmentioning

confidence: 99%

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

Lam

Yeap

Rasoli

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

Newcastle disease virus (NDV) is an avian virus that causes deadly infection to over 250 species of birds, including domestic and wild-type, thus resulting in substantial losses to the poultry industry worldwide. Many reports have demonstrated the oncolytic effect of NDV towards human tumor cells. The interesting aspect of NDV is its ability to selectively replicate in cancer cells. Some of the studies have undergone human clinical trials, and favorable results were obtained. Therefore, NDV strains can be the potential therapeutic agent in cancer therapy. However, investigation on the therapeutic perspectives of NDV, especially human immunological effects, is still ongoing. This paper provides an overview of the current studies on the cytotoxic and anticancer effect of NDV via direct oncolysis effects or immune stimulation. Safety of NDV strains applied for cancer immunotherapy is also discussed in this paper.

show abstract

Section: Immunostimulatory Property Of Ndvmentioning

confidence: 99%

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

Lam

Yeap

Rasoli

et al. 2011

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…NDV is an avian virus, but is capable of infecting non-avian species including cattle (3, 53). NDV is attenuated in non-avian species due to a natural host-range restriction.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, NDV has been evaluated in non-human primates as a potential vaccine vector for human use (6, 17). In addition, NDV has been used as an oncolytic agent against bovine papillomatosis in cattle and has been shown to be safe in repeated inoculations (3). NDV shares only a low level of amino acid sequence identity with bovine paramyxoviruses and is antigenically distinct, suggesting that the entire bovine population would be susceptible to infection with a NDV vectored vaccine.…”

Section: Discussionmentioning

confidence: 99%

Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1

Khattar

Collins

Samal

2010

Vaccine

View full text Add to dashboard Cite

Bovine herpesvirus-1 (BHV-1) is a major cause of respiratory tract diseases in cattle. Vaccination of cattle against BHV-1 is a high priority. A major concern of currently modified live BHV-1 vaccines is their ability to cause latent infection and subsequent reactivation resulting in many outbreaks. Thus, there is a need for alternative strategies. We generated two recombinant Newcastle disease viruses (NDVs) expressing the glycoprotein D (gD) of BHV-1 from an added gene. One recombinant, rLaSota/gDFL, expressed gD without any modification. The other recombinant, rLaSota/gDF, expressed a chimeric gD in which the ectodomain of gD was fused with the transmembrane domain and cytoplasmic tail of the NDV fusion F glycoprotein. Remarkably, the native gD expressed by rLaSota/gDFL virus was incorporated into the NDV virion 2.5-fold more efficiently than the native NDV proteins, whereas the chimeric gD was not detectably incorporated even though it was abundantly expressed on the infected cell surface. The expression of gD did not increase the virulence of the rNDV vectors in chickens. A single intranasal and intratracheal inoculation of calves with either recombinant NDV elicited mucosal and systemic antibodies specific to BHV-1, with the responses to rLaSota/gDFL being higher than those to rLaSota/gDF. Following challenge with BHV-1, calves immunized with the recombinant NDVs had lower titers and earlier clearance of challenge virus compared to the empty vector control, and reduced disease was observed with rLaSota/gDFL. Following challenge, the titers of serum antibodies specific to BHV-1 were higher in the animals immunized with the rNDV vaccines compared to the rNDV parent virus, indicating that the vaccines primed for secondary responses. Our data suggest that NDV can be used as a vaccine vector in bovines and that BHV-1 gD may be useful in mucosal vaccine against BHV-1 infection, but might require augmentation by a second dose or the inclusion of additional BHV-1 antigens.

show abstract

“…The scoring system used in this study had not been previously validated, to the authors’ knowledge, because there are no other detailed clinical trials on dogs with papillomatosis. This scoring system, however, was purposely designed to evaluate both the extent and the severity of the disease as in other accepted scoring systems used in veterinary and human medicine 14–21 …”

Section: Discussionmentioning

confidence: 99%

Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double‐blinded, placebo‐controlled clinical trial

Yağci

Ural²,

Öcal

et al. 2008

Veterinary Dermatology

View full text Add to dashboard Cite

Azithromycin, an azalide subclass macrolide antibiotic, is an effective, well-tolerated and safe therapeutic option for treatment of papillomatosis in humans. This study reports the clinical and histopathological results from a prospective, randomized, double-blinded, placebo-controlled trial of 17 dogs of various breeds with diagnosis of oral (n = 12) and cutaneous papillomatosis (n = 5) treated with azithromycin. Papillomas appeared as whitish, verrucous, hyperkeratotic papules 1-2.7 mm in size. The cases were randomly assigned to azithromycin (n = 10) and placebo treatment groups (n = 7). Both owners and investigators were blinded to the allocation to the groups. Azithromycin (10 mg/kg) was administered per os every 24 h for 10 days. Clinical evaluations were done by the same investigator throughout the trial. Azithromycin treatment significantly decreased clinical scores (P < 0.001), whereas there was no change seen in the placebo group. In the azithromycin treatment group, skin lesions disappeared in 10-15 days. One case in the placebo had spontaneous regression of its papillomas by day 41, but lesions were still evident at day 50 in the remaining six cases. There was no recurrence of papillomatosis in the azithromycin treated dogs (follow up 8 months). No adverse effects were seen in either group. In conclusion, azithromycin appears to be a safe and effective treatment for canine papillomatosis.

show abstract

Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis

Cited by 13 publications

References 15 publications

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1

Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double‐blinded, placebo‐controlled clinical trial

Contact Info

Product

Resources

About